 |
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2016, vol. 22, issue 1
Subject Area: Medicine
Pages: 1039-1044
DOI: 10.5272/jimab.2016221.1039
Published online: 10 March 2016
J of IMAB 2016 Jan-Mar;22(1):1039-1044
FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES
Assia Konsoulova1* 
, Ivan Donev1*, Nikolay Conev1, Sonya Draganova1, Nadezhda Petrova2, Eleonora Dimitrova1, Hristo Popov2, Kameliya Bratoeva3, Petar Ghenev2.
1) Medical Oncology Clinic, University Hospital “St. Marina”- Varna
2) General and specialized pathology Clinic, University Hospital “St. Marina”- Varna
3) Division of pathophysiology, Department of Physiology and pathophysiology, Medical University, Varna, Bulgaria.
* Those authors participated with equal contribution to this publication.
ABSTRACT:
Purpose: Colorectal cancer is the second leading cause of cancer mortality in the USA. According to Bulgarian National Statistics Institute, 2370 colon and 1664 rectal cancer cases were diagnosed in 2012 with total number of patients 29995. Adding bevacizumab to chemotherapy in patients with metastatic disease improves progression-free survival (PFS) but no predictive markers have been proven in the clinical practice. In our study we examined two tissue biomarkers that may correlate with response to bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer.
Patients and Methods: 54 patients with metastatic colorectal cancer were assigned to first line 5-Fu-based chemotherapy with/without bevacizumab. The primary end point was PFS, with additional determination of response and toxicity. Paraffin-embedded samples from primary tumors were collected from all 54 patients. Expression levels of two tumor biomarkers VEGFR-2 and Neuropilin 1 (NP-1) were evaluated with immunohistochemistry.
Results: The median PFS for the group treated with CT/Bev was 8.8 months, compared with 5.4 months for the group with chemotherapy alone (95% CI, log-rank test P =0.003). The corresponding overall response rates were 19.3% and 10.2% respectively (P < 0.05 for CT/Bev vs CT). Patients with low NP-1 had statistically significant prolongation of PFS as compared to those with high NP-1 (95% CI, log rank test p= 0.017). Patients with low NP-1 appeared to experience a larger bevacizumab treatment effect in terms of PFS (p=0,049,HR 0.333, 95% CI, 0.111 to 0.995) than patients with high NP-1.
Conclusion: The addition of bevacizumab to 5-Fu based chemotherapy improves PFS for patients with metastatic colorectal cancer. Expression of tumor NP-1 is a potential biomarker candidate for prediction of clinical outcome in patients with metastatic colorectal cancer, treated with first line chemotherapy plus bevacizumab.
Key words: colorectal, bevacizumab, VEGFR-2, biomarkers, neuropillin-1,
- Download FULL TEXT /PDF 651 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Konsoulova A, Donev I, Conev N, Draganova S, Petrova N, Dimitrova E, Popov H, Bratoeva K, Ghenev P. First line 5-Fu-based chemotherapy with/without Bevacizumab for Metastatic Colorectal Cancer: tissue biomarker candidates. J of IMAB. 2016 Jan-Mar;22(1):1039-1044.
DOI: http://dx.doi.org/10.5272/jimab.2016221.1039.
Correspondence to: Dr. Assia Konsoulova-Kirova, University Hospital “Sveta Marina”; 1, Hristo Smirnenski Blvd., 9001 Varna, Bulgaria; E-mail: dr.konsoulova@gmail.com
REFERENCES:
1. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med. 1971 Nov;285(21):1182-1186. [PubMed] [CrossRef].
2. Brower V. Evidence of efficacy: researchers investigating markers for angiogenesis inhibitors. J Natl Cancer Inst. 2003 Oct;95(19):1425-7. [PubMed] [CrossRef].
3. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med. 2003 Nov;3(7):643-51. [PubMed] [CrossRef].
4. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002 Oct;2(10):795-803. [PubMed] [CrossRef].
5. McColl BK, Stacker SA, Achen MG. Molecular regulation of the VEGF family - inducers of angiogenesis and lymphangiogenesis. APMIS. 2004 Jul-Aug;112(7-8):463-80. [PubMed] [CrossRef].
6. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004 May;3(5):391-400. [PubMed] [CrossRef].
7. Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, et al. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC cancer. 2011 Jun;11:247. [PubMed] [CrossRef].
8. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011 May;473(7347):298-307. [PubMed] [CrossRef].
9. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998 Mar;92(6):735-45. [PubMed] [CrossRef].
10. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nat Cancer Inst. 2000 Feb;92(3):205-16. [PubMed] [CrossRef].
11. Dinse GE, Lagakos SW. Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. Biometrics. 1982;38(4):921-32. [PubMed].
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163-70. [PubMed].
13. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.J Clin Oncol. 2003 Jan;21(1):60-5. [PubMed] [CrossRef].
14. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun;350(23):2335-42. [PubMed] [CrossRef].
15. Chong G, Tebbutt NC. Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Adv Med Oncol. 2010 Sep;2(5):309-17. Epub 2011/07/27. [PubMed] [CrossRef].
16. Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007 Apr;25(12):1539-44. [PubMed] [CrossRef].
17. Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Maspero F, et al. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer. 2013 Sep;12(3):145-51. [PubMed] [CrossRef].
18. Foernzler D, Delmar P, Kockx M, Cassidy J, Saltz L, Scherer S, et al. Tumor tissue based biomarker analysis in NO16966: A randomized phase III study of first-line bevacizumab in combination with oxaliplatin-based chemotherapy in patients with mCRC. 2010 ASCO Gastrointestinal Cancers Symposium. January 22-24, 2010, Orlando, FL. Abstr. 374.
Received: 11 December 2015
Published online: 10 March 2016